Multiple Sclerosis, Primary Progressive Clinical Trial
Official title:
The Effect of Variable Intensity Work on Postural Instability, Motion Performance and Quality of Life in Multiple Sclerosis Patients
Abstract Introduction: Postural control disorders are the most common motor disorder
associated with multiple sclerosis.
Objective: The aim of this study is to demonstrate the potential for improvement of postural
control, motion performance and quality of life in patients with multiple sclerosis who are
performing a special neurorevolutionary balancing program.
Intervention: The treated group (n = 15) performed five times a week for the treatment we
defined. (60 minutes per day). The experimental group performed movements using the Xbox 360
and Kinect consoles. The study team participated in 25 sessions, five times a week. The
duration of treatment was 5 weeks.The MStp group (n=14) participated in a 5-week
physiotherapy course. The general treatment consisted of strengthening, stretching and
walking correction. During the 5-week period, 25 patients attended training. One treatment
takes 60 minutes. Sensory Organisation Test / Body Sway at the end of the baseline and
treatment protocol is used to evaluate each patient. The quality of life mapping was measured
by subjective tests (EQ-5D-5L, ADL). To assess the depressive state, a Beck depression
questionnaire was used. Balance and motion performance were used by the Berg Balance Test and
6Minutes Walk Test. The results were compared with the control group results (n = 14) and
showed improvement in overall balance and motion performance.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03455582 -
Cognition Evolution and MRI Markers in PPMS Patients on 2 Years
|
N/A | |
| Active, not recruiting |
NCT04544449 -
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT04918225 -
Motor Asymmetry in Progressive Multiple Sclerosis Patients
|
||
| Completed |
NCT02913157 -
Hydroxychloroquine in Primary Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT01982942 -
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05204459 -
MS-ResearchBiomarkerS
|
||
| Recruiting |
NCT05663853 -
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
|
||
| Completed |
NCT01194570 -
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT02305264 -
Imaging of Intracerebral Inflammation in MS
|
N/A | |
| Completed |
NCT03679468 -
Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation
|
N/A | |
| Recruiting |
NCT05496881 -
Exercise Effects in Multiple Sclerosis
|
N/A | |
| Completed |
NCT02506751 -
Open-label Study of Liothyronine in MS
|
Phase 1 | |
| Temporarily not available |
NCT02606929 -
Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
|
Phase 0 | |
| Completed |
NCT04545372 -
Aerobic Exercises for Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT05122559 -
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT02988401 -
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02632591 -
Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment
|
Phase 1 | |
| Completed |
NCT01917019 -
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT01433497 -
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
|
Phase 3 | |
| Not yet recruiting |
NCT05385731 -
MUSCLE - Nordic Walking in MUltiple SCLErosis
|
N/A |